HMGB1/Bcl-2表达与结直肠癌患者化疗耐药及预后关系的研究

目的研究肿瘤组织内高迁移率蛋白族1（High mobility group box 1，HMGB1）和Bcl-2表达与结直肠癌（CRC）化疗耐药及预后的关系。 方法采用免疫组化法分析97名CRC患者肿瘤组织中HMGB1和Bcl-2的表达强度，并分析其与CRC不同临床病理特征、患者总生存期及化疗反应率间的关系。 结果中分化、低分化CRC中HMGB1高表达率和Bcl-2阳性表达率显著高正常组织（P<0.05）。HMGB1表达与CRC患者淋巴浸润、脉管浸润及化疗反应率显著相关（P<0.05），与其他临床病理特征及患者总生存期无显著相关性（P>0.05）。Bcl-2表达与患者临床病理特征及总生存期无显著相关性（P>0.05），但与化疗反应率显著相关（P<0.05）。 结论HMGB1高表达和Bcl-2阳性表达可用于预示CRC化疗耐药，HMGB1高表达可作为CRC预后的预测指标。

Impact of HMGB1 expression and Bcl-2 expression on chemoresistance and prognosis in colorectal cancer

ObjectiveTo investigate the impact of HMGB1 expression and Bcl-2 expression on chemo-resistance and prognosis of colorectal cancer (CRC). MethodHMGB1 expression and Bcl-2 expression in CRC tumor tissues from 97 patients was analyzed by immunohistochemistry. Relationship among HMGB1 high expression, Bcl-2 positive expression, clinical histological features, overall survival and chemotherapy response rate were compared. ResultsHMGB1 high expression rates and Bcl-2 positive expression rates in low differentiated and differentiation CRC specimens were significant higher than that in high differentiated tissues (P<0.05). Lymphatic invasion, venous invasion and chemotherapy response rate showed significant correlation with HMGB1 expression (P<0.05). Chemotherapy response rate was also significantly affected by Bcl-2 expression (P<0.05). ConclusionsHMGB1 high expression and Bcl-2 positive expression may be used to predict chemo-resistance. HMGB1 high expression may be used as predictors of CRC prognosis.